IV: $$$

Spectrum of Activity

General Information

  • ODB Funded (injection)

  • EAP (10g/vial Injection)


  • Dermatologic: Skin tightness (IM: ≤5% to ≤17%; local)

  • Local: Induration at injection site (≤5% to ≤17%; incidence higher with IM), warm sensation at injection site (IM: ≤5% to ≤17%)

1% to 10%:

  • Dermatologic: Skin rash (2%)

  • Gastrointestinal: Diarrhea (3%)

  • Hematologic & oncologic: Eosinophilia (6%), leukopenia (2%), thrombocythemia (5%)

  • Hepatic: Increased serum transaminases (3%)

  • Local: Pain at injection site (≤1%), tenderness at injection site (≤1%)

  • Renal: Increased blood urea nitrogen (1%)

CBC with differential, platelet count, PT, renal and hepatic function tests periodically; number and type of stools/day for diarrhea; observe for signs and symptoms of anaphylaxis

Calcium containing IV solutions bind to ceftriaxone forming an insoluble precipitate - avoid concurrent use with calcium contaning colutions in neonates

  • For meningitis, administration of dexamethasone prior to first dose of ceftriaxone may be considered

    • Divide doses >2 g/day (q12h)
  • Fatal cases of ceftriaxone-calcium precipitation have been reported

    • May administer IV ceftriaxone at the same time, but via a different infusion line than calcium-containing IV solutions